Nuvation Bio
$6.81
86
+$0.04+0.59% 19:59 Today
+$0.08+1.21%20:47After hours
Statistics
Day High
6.87
Day Low
6.72
52W High
9.75
52W Low
2.99
Volume
3,755,199
Avg. Volume
6,776,226
Mkt Cap
2.39B
P/E Ratio
-
Dividend Yield
-
Dividend
-
Upcoming
Earnings
11NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.18
-0.12
-0.05
0.01
Expected EPS
-0.116865
Actual EPS
N/A
Financials
-325.31%Profit Margin
Unprofitable62.9MRevenue
-204.63MNet Income
Analyst Ratings
16.25Average Price Target
The highest estimate is 21.00.
From 5 ratings within the last 6 months. This is not an investment recommendation.
From 5 ratings within the last 6 months. This is not an investment recommendation.
Buy 100%
Hold 0%
Sell 0%
People Also Follow
This list is based on the watchlists of people on Stock Events who follow NUVB. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
Bristol-Myers Squibb
BMY
Mkt Cap136B
Merck
MRK
Mkt Cap366B
Pfizer
PFE
Mkt Cap159.36B
Gilead Sciences
GILD
Mkt Cap180.64B
AMGEN
AMGN
Mkt Cap233.78B
Abbvie
ABBV
Mkt Cap451.46B
Regeneron Pharmaceuticals
REGN
Mkt Cap81.77B
Astrazeneca
AZN
Mkt Cap252.33B
Novartis
NVS
Mkt Cap292.35B
Johnson & Johnson
JNJ
Mkt Cap645.95B
About
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.
Show more...
CEO
David T. Hung
Employees
305
Country
United States
ISIN
US67080N1019
WKN
000A2QPAG
Listings
0 Comments
Share your thoughts
FAQ
What is Nuvation Bio stock price today?▼
The current price of NUVB is $6.81 USD — it has increased by +0.59% in the past 24 hours. Watch Nuvation Bio stock price performance more closely on the chart.
What is Nuvation Bio stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNYS exchange Nuvation Bio stocks are traded under the ticker NUVB.
Is Nuvation Bio stock price growing?▼
NUVB stock has risen by +2.25% compared to the previous week, the month change is a +5.75% rise, over the last year Nuvation Bio has showed a +99.12% increase.
What is Nuvation Bio market cap?▼
Today Nuvation Bio has the market capitalization of 2.39B
When is the next Nuvation Bio earnings date?▼
Nuvation Bio is going to release the next earnings report on November 11, 2026.
What were Nuvation Bio earnings last quarter?▼
NUVB earnings for the last quarter are -0.18 USD per share, whereas the estimation was -0.14 USD resulting in a -27.06% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Nuvation Bio revenue for the last year?▼
Nuvation Bio revenue for the last year amounts to 62.9M USD.
What is Nuvation Bio net income for the last year?▼
NUVB net income for the last year is -204.63M USD.
How many employees does Nuvation Bio have?▼
As of September 04, 2026, the company has 305 employees.
In which sector is Nuvation Bio located?▼
Nuvation Bio operates in the Health & Wellness sector.
When did Nuvation Bio complete a stock split?▼
Nuvation Bio has not had any recent stock splits.
Where is Nuvation Bio headquartered?▼
Nuvation Bio is headquartered in NEW YORK, United States.